About Imagenomix
Imagenomix Corp is a biotechnology company rooted in leading U.S. academic research, with a team strongly connected to Greek scientific talent. The company addresses a critical gap in oncology diagnostics, where pathology is central to cancer diagnosis and treatment decisions but often lacks timely and comprehensive molecular insights.
Imagenomix has developed an AI-driven approach that infers molecular genotypes directly from standard H&E pathology slides, eliminating the need for additional tissue samples and significantly reducing the typical multi-week turnaround time for results. It is also our first investment from the Brain Gain Fund.
News and Update
Metavallon VC invests in Imagenomix via the Brain Gain Fund, backing AI cancer diagnostics that make precision oncology faster and more accessible. For more information
Co-investors:
